These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35998514)

  • 21. Immunotherapy and breast cancer: an overview.
    Mezni E; Behi K; Gonçalves A
    Curr Opin Oncol; 2022 Sep; 34(5):587-594. PubMed ID: 35838204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The landscape of systemic therapy for early stage triple-negative breast cancer.
    Lu JY; Alvarez Soto A; Anampa JD
    Expert Opin Pharmacother; 2022 Aug; 23(11):1291-1303. PubMed ID: 35818711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the systemic treatment of triple-negative breast cancer.
    Lebert JM; Lester R; Powell E; Seal M; McCarthy J
    Curr Oncol; 2018 Jun; 25(Suppl 1):S142-S150. PubMed ID: 29910657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
    Beyerlin K; Jimenez R; Zangardi M; Fell GG; Edmonds C; Johnson A; Bossuyt V; Specht M; Mulvey TM; Moy B; Ellisen LW; Isakoff SJ; Bardia A; Spring LM
    J Oncol Pharm Pract; 2021 Dec; 27(8):1883-1890. PubMed ID: 33153384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response.
    De Santis P; Perrone M; Guarini C; Santoro AN; Laface C; Carrozzo D; Oliva GR; Fedele P
    Explor Target Antitumor Ther; 2024; 5(1):232-250. PubMed ID: 38464390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.
    Chun B; Pucilowska J; Chang S; Kim I; Nikitin B; Koguchi Y; Redmond WL; Bernard B; Rajamanickam V; Polaske N; Fields PA; Conrad V; Schmidt M; Urba WJ; Conlin AK; McArthur HL; Page DB
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
    Barroso-Sousa R; Tolaney SM
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer.
    Pereira MFI; Buzatto IPC; Carrara HHA; Buono FO; de Andrade JM; Orlandini LF; Tiezzi DG
    Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 39176205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer.
    Myers SP; Sevilimedu V; Jones VM; Abuhadra N; Montagna G; Plitas G; Morrow M; Downs-Canner SM
    Ann Surg Oncol; 2024 Aug; 31(8):5180-5188. PubMed ID: 38767803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations.
    Santa-Maria CA; O'Donnell M; Nunes R; Wright JL; Stearns V
    J Natl Compr Canc Netw; 2022 Jul; 20(7):738-744. PubMed ID: 35830893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.
    Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neo-adjuvant therapy for triple-negative breast cancer: Insights from a network meta-analysis.
    Miyashita H; Satoi S; Cruz C; Malamud SC
    Breast J; 2020 Sep; 26(9):1717-1728. PubMed ID: 32657479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
    Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of immune checkpoint inhibition in triple negative breast cancer.
    Tarekegn K; Keskinkilic M; Kristoff TJ; Evans ST; Kalinsky K
    Expert Rev Anticancer Ther; 2023; 23(10):1095-1106. PubMed ID: 37771270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
    Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
    Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letter to the Editor Regarding "Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States".
    Sorscher S
    Adv Ther; 2023 Sep; 40(9):4111-4113. PubMed ID: 37432550
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.